

July 16, 2019

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)

Announcement of New Management Team

HEALIOS K.K. (“Healios”) today announces the appointment of new executive officers and its new management team as below.

(1) New Executive Officers

Richard P. Kincaid, Executive Officer & CFO

Richard P. Kincaid has been a financial industry professional in Japan and Asia for the past 19 years. He started his career at Goldman Sachs in Japan, and then in 2004 he established a hedge fund management firm based in Hong Kong, Nezu Asia Capital Management, where he has been a partner for over 15 years. He has served as a director of Healios since March 2018.

David W. Smith, Executive Officer in charge of manufacturing

David W. Smith is one of the world’s foremost experts on cell manufacturing. He began his career as a pharmacist, and then experienced various roles in the pharmaceutical industry. Since 2002 he led a cell therapy contract manufacturing business, then served as the Vice President, Global Business Development for Lonza Corporation, one of the largest cell therapy manufacturing service organizations in the industry. He has served as a director of Healios since March 2018, and then assumed the role of Chief Commercial Officer of Healios NA, Inc. in August 2018.

Koji Abe, Executive Officer in charge of human resources and general affairs

Koji Abe has 30 years of experience in the human resource field at technology R&D companies. He started his work in the HR field in 1989, after serving as a sales accountant at Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.). After working at a US subsidiary, he led personnel operations related to corporate re-organization. In 2005 he joined Sysmex Corporation and revised the personnel framework and established a new talent development program as Vice President, and then Executive Vice President of HR. He joined Healios in April 2019.

(2) Management Team

Chairman and CEO	Hardy TS Kagimoto, MD,
Executive Vice President* ¹ CMO (Chief Medical Officer)	Masanori Sawada, MD, PhD, MBA
Executive Officer in charge of research Head of Kobe Research Institute	Kouichi Tamura, PhD
Executive Officer in charge of development	Michihisa Nishiyama
Executive Officer CFO	Richard P. Kincaid
Executive Officer in charge of manufacturing	David W. Smith* ²
Executive Officer in charge of HR and GA	Koji Abe

*1 Mr. Sawada newly assumes the position of Executive Vice President.

*2 Mr. Smith concurrently serves as Chief Commercial Officer of Healios NA, Inc., our United States based subsidiary company.

Hardy TS Kagimoto, MD, Chairman and CEO of Healios commented as below:

“I am pleased to be able to appoint each of Mr. Kincaid, Mr. Smith and Mr. Abe as executive officers. Further, Mr. Sawada, who has led Healios since its establishment, was appointed to Executive Vice President.

We have built a robust management team to streamline our capabilities as a pharmaceutical company that aims to research, develop, manufacture and promote regenerative medicine and cell therapy. We have over 100 employees and are running two pivotal trials, and these management appointments reflect the ongoing maturation of our business. At the same time, they demonstrate our momentum as a Japan based bio-venture company that can compete on a global scale.

Healios is developing stem cell platform technologies to deliver innovative treatments to patients suffering from unmet medical needs. We will strengthen our leadership and work even harder to achieve our mission, ‘To foster a Life Explosion that enriches the lives of people around the world.’”